Morgan Maeder has over a 15 years of experience in the field of Gene Editing. She obtained her PhD from Harvard University in the lab of J. Keith Joung, where her work spanned multiple platforms, from zinc fingers and TALEs to CRISPR-Cas9, and from nuclease-based gene editing to epigenetic-based gene regulation. In 2013, she joined Editas Medicine as the first Scientist. At Editas, she led the development of EDIT-101, a CRISPR-Cas9-based gene editing approach to treat of Leber Congenital Amaurosis type 10. EDIT-101 became the first in vivo use of a CRISPR genome editing medicine with the dosing of the first patient in the BRILLIANCE clinical trial in March of 2020. Following her time at Editas, Morgan spent a year and a half as a consultant to Third Rock Ventures helping to launch Faze Medicines, a biotech company pioneering therapeutics based on the science of biomolecular condensates and their formation through the process of liquid liquid phase separation. In the summer of 2020, she joined Chroma Medicine, where she currently works as a Senior Director of Payload Sciences. At Chroma, Morgan works to develop programmable epigenetic editors to specifically modulate gene expression and provide novel, durable treatment options to patients suffering from a wide range of genetically treatable diseases.